The Bayer Aktie (Bayer stock) experienced a dramatic sell-off this week, alarming both investors and market analysts. On Wednesday, the stock dropped by a staggering 7.68%, closing at just €25.60—a critical level that threatens to break the stock’s recent upward trend. The sharp decline was triggered by disappointing quarterly results and renewed concerns about ongoing legal risks related to the company’s glyphosate-based weed killer business.
Disappointing Results Undermine Market Confidence
Bayer released its updated forecast for 2025, predicting revenue between €44 and €46 billion, which is €500 million lower than previous expectations. While EBITDA is projected to remain steady between €9.2 and €9.7 billion, this failed to impress investors who were hoping for signs of recovery or growth.
More concerning, however, was the CEO’s public statement regarding Bayer’s controversial Roundup product. CEO Bill Anderson admitted that the company might abandon the Roundup project entirely if legal risks can’t be resolved. This would potentially lead to multi-billion-euro losses and intensifies the uncertainty around Bayer’s legal liabilities in the U.S.
Technical Breakdown: €25 Level Becomes Key Support
Technical analysts now see the €25 level as a crucial support line. A breakdown below this level could push the Bayer Aktie further into bearish territory. Earlier analyst price targets above €28 are likely to be revised downward given the deteriorating sentiment and market dynamics.
From a chart perspective, the Bayer stock has come under heavy pressure. The current technical pattern suggests weakness, and momentum indicators are pointing to a bearish shift unless the stock can quickly stabilize above key support zones.
External Pressures Add to Internal Woes
Beyond financial performance and legal risks, Bayer is also facing criticism for its external spending. The company’s high-profile sponsorship deals in the Bundesliga football league have raised eyebrows, especially as economic headwinds continue. These non-core expenses could further strain the company’s balance sheet, which is already under pressure from debt and legal settlements.
Combined, these factors contribute to an increasingly complex and fragile investment case for Bayer in the near term.
Should You Buy or Sell Bayer Aktie?
The big question for investors is whether the Bayer Aktie still represents a buy. At its current price, some value-oriented investors may see an opportunity, especially if the company manages to resolve its legal challenges. However, short-term risks remain high, and any further negative developments—either in court or from the company’s earnings—could send the stock even lower.
A recent analysis dated August 7 emphasized that immediate action is required for Bayer shareholders. While the long-term outlook could improve, near-term volatility is almost guaranteed, making it a stock for risk-tolerant investors only.
Stay informed with the latest in startup news, financial trends, and innovation. Visit Startup News for daily updates and exclusive insights.
